Paper · 28418444
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ and 17 others. JAMA Oncol, 2017. Cited by 479 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Papers, record 28418444. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28418444
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics32
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ataxia Telangiectasia Mutated Proteins | Major topic |
| Breast Neoplasms | Major topic |
| Checkpoint Kinase 2 | Major topic |
| DNA-Binding Proteins | Major topic |
| Genetic Predisposition to Disease | Major topic |
| Nuclear Proteins | Major topic |
| Ovarian Neoplasms | Major topic |
| Tumor Suppressor Proteins | Major topic |
| Ubiquitin-Protein Ligases | Major topic |
| Acid Anhydride Hydrolases | |
| Adult | |
| Case-Control Studies | |
| Cell Cycle Proteins | |
| Cyclin-Dependent Kinase Inhibitor p16 | |
| Cyclin-Dependent Kinase Inhibitor p18 | |
| DNA Repair Enzymes | |
| Fanconi Anemia Complementation Group N Protein | |
| Fanconi Anemia Complementation Group Proteins | |
| Female | |
| Genetic Testing | |
| Germ-Line Mutation | |
| Humans | |
| MRE11 Homologue Protein | |
| Middle Aged | |
| Mismatch Repair Endonuclease PMS2 | |
| MutL Protein Homolog 1 | |
| MutS Homolog 2 Protein | |
| Neurofibromin 1 | |
| Phenotype | |
| RNA Helicases | |
| Risk Factors | |
| White People |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R25 CA092049 | NCI NIH HHS | United States | R25CA092049 | PubMed and NIH | NIH RePORTER |
| U01 CA116167 | NCI NIH HHS | United States | R01CA116167 | PubMed and NIH | NIH RePORTER |
| R01 CA116167 | NCI NIH HHS | United States | R01CA116167 | PubMed and NIH | NIH RePORTER |
| P50 CA116201 | NCI NIH HHS | United States | P50CA116201 | PubMed and NIH | NIH RePORTER |
| R01 CA192393 | NCI NIH HHS | United States | R01CA192393 | PubMed and NIH | NIH RePORTER |
| U01CA116167 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07532434 | A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer | Background |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 28,418,452 | Multigene Panel Testing and Breast Cancer Risk: Is It Time to Scale Down? | https://conductscience.org/library/papers/28418452 | PubMed |
| Comment in | 29,285,541 | Ascertainment Bias and Estimating Penetrance. | https://conductscience.org/library/papers/29285541 | PubMed |
References24
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23,510,156 | Risk of breast cancer in Lynch syndrome: a systematic review. | Breast Cancer Res | 2013 | https://conductscience.org/library/papers/23510156 | PubMed |
| 2 | 27,433,846 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27433846 | PubMed |
| 3 | 26,720,728 | Inherited Mutations in Women With Ovarian Carcinoma. | JAMA Oncol | 2016 | https://conductscience.org/library/papers/26720728 | PubMed |
| 4 | 26,014,596 | Gene-panel sequencing and the prediction of breast-cancer risk. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26014596 | PubMed |
| 5 | 26,681,312 | Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. | Genet Med | 2016 | https://conductscience.org/library/papers/26681312 | PubMed |
| 6 | 17,033,622 | Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. | Nat Genet | 2006 | https://conductscience.org/library/papers/17033622 | PubMed |
| 7 | 24,763,289 | Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. | Genet Med | 2014 | https://conductscience.org/library/papers/24763289 | PubMed |
| 8 | 23,165,953 | Increased risk of breast cancer in women with NF1. | Am J Med Genet A | 2012 | https://conductscience.org/library/papers/23165953 | PubMed |
| 9 | 26,921,362 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. | J Med Genet | 2016 | https://conductscience.org/library/papers/26921362 | PubMed |
| 10 | 25,099,575 | Breast-cancer risk in families with mutations in PALB2. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25099575 | PubMed |
1 to 10 of 24
See all 24 referencesCited by352
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 479 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,887,902 | Real-World Germline Variant Landscape and Clinical Management in Korean Patients Tested for Suspected Hereditary Cancer. | Cancer Sci | 2026 | https://conductscience.org/library/papers/42887902 | PubMed |
| 42,878,904 | Moderate-risk variants in hereditary breast and ovarian cancer: seven-year experience from a specialized center. | Fam Cancer | 2026 | https://conductscience.org/library/papers/42878904 | PubMed |
| 42,527,799 | Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer by Age, Race, and Tumor Subtype. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/42527799 | PubMed |
| 42,306,566 | Impact of germline RAD51D mutations on breast cancer: Susceptibility to DNA-damaging agents. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42306566 | PubMed |
| 42,162,002 | AI-genomics synergy for drug repurposing in breast cancer: an interpretability-driven framework. | NPJ Genom Med | 2026 | https://conductscience.org/library/papers/42162002 | PubMed |
| 42,126,782 | Prevalence and clinical significance of germline pathogenic variants identified by multigene panel testing in high-risk Japanese patients with breast cancer. | Breast Cancer | 2026 | https://conductscience.org/library/papers/42126782 | PubMed |
| 42,014,738 | Multimodal analysis of a rare BARD1 missense variant suggests its pathogenicity is conditional. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/42014738 | PubMed |
| 42,011,088 | High Prevalence of Non-BRCA Pathogenic Variants and a Recurrent PALB2 Variant in an Argentine Hereditary Breast and Ovarian Cancer Cohort. | Cancer Med | 2026 | https://conductscience.org/library/papers/42011088 | PubMed |
| 41,978,872 | Genetic Testing in Breast Cancer: Narrative Review and Clinical Insights. | Maedica (Bucur) | 2026 | https://conductscience.org/library/papers/41978872 | PubMed |
| 41,896,856 | Age-related genomic characterization and therapeutic targets in Chinese breast cancer: insights from prospective targeted sequencing and clinical data analysis. | BMC Med | 2026 | https://conductscience.org/library/papers/41896856 | PubMed |
1 to 10 of 352
See all 352 cited byGenes22
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATM | 472 | PubTator's text mining | https://conductscience.org/library/genes/472 | NCBI Gene |
| BARD1 | 580 | PubTator's text mining | https://conductscience.org/library/genes/580 | NCBI Gene |
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| BRCA2 | 675 | PubTator's text mining | https://conductscience.org/library/genes/675 | NCBI Gene |
| BRIP1 | 83,990 | PubTator's text mining | https://conductscience.org/library/genes/83990 | NCBI Gene |
| CDH1 | 999 | PubTator's text mining | https://conductscience.org/library/genes/999 | NCBI Gene |
| CDKN2A | 1,029 | PubTator's text mining | https://conductscience.org/library/genes/1029 | NCBI Gene |
| CHEK2 | 11,200 | PubTator's text mining | https://conductscience.org/library/genes/11200 | NCBI Gene |
| MLH1 | 4,292 | PubTator's text mining | https://conductscience.org/library/genes/4292 | NCBI Gene |
| MRE11 | 4,361 | PubTator's text mining | https://conductscience.org/library/genes/4361 | NCBI Gene |
1 to 10 of 22
See all 22 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28418444
GET https://conductscience.org/api/papers/v1/28418444/references?page=2